Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead

1 Dec 2022

Abstract excerpt

RAD51 is integral in homologous recombination DNA damage repair and has garnered much interest as both a biomarker and potential therapeutic target in oncology. Multiple in vitro and in vivo studies have demonstrated its role as a predictive marker, particularly in the context of platinum-based therapies and poly ADP-ribose polymerase (PARP) inhibitors. In this review, we highlight the development of RAD51...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36536949
DOI: 10.2147/ott.s322297

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges AheadPMID 36536949Read ↗

RAD51 as a potential surrogate marker for DNA repair capacity in solid malignanciesSemantic proximity Read ↗

Regulation and pharmacological targeting of RAD51 in cancerSemantic proximity Read ↗

Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51Semantic proximity Read ↗

RAD51 Is Implicated in DNA Damage, Chemoresistance and Immune Dysregulation in Solid TumorsSemantic proximity Read ↗

New RAD51 Inhibitors to Target Homologous Recombination in Human CellsSemantic proximity Read ↗

RAD51 and PALB2 in precision oncology: Clinical implications for HRD associated breast and ovarian cancers (Review)Semantic proximity Read ↗

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient StratificationSemantic proximity Read ↗

RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?Semantic proximity Read ↗

RAD51 as a potential biomarker and therapeutic target for pancreatic cancerSemantic proximity Read ↗

Variation in RAD51 details a hub of functions: opportunities to advance cancer diagnosis and therapySemantic proximity Read ↗

Targeting DNA Double-Strand Break (DSB) Repair to Counteract Tumor Radio-resistanceSemantic proximity Read ↗

A Pan-Cancer Bioinformatic Analysis of RAD51 Regarding the Values for Diagnosis, Prognosis, and Therapeutic PredictionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.